Why is it critical to achieve a deep molecular response in chronic myeloid leukemia?

por Branford, Susan
Publicado 2020

BCR::ABL1 transcripts and clinical outcome ‐ interrogating the technique

por Branford, Susan
Publicado 2022

Initial Rate of BCR::ABL1 Decline for Response Prediction in Chronic Myeloid Leukemia

por Branford, Susan
Publicado 2022

NGS in CML - New standard diagnostic procedure?

por Branford, Susan, Shanmuganathan, Naranie
Publicado 2019

Measurable residual disease in chronic myeloid leukemia

por Branford, Susan, Apperley, Jane F.
Publicado 2022

Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia

por Fernandes, Adelina, Shanmuganathan, Naranie, Branford, Susan
Publicado 2022

Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication

por Shahrin, Nur Hezrin, Wadham, Carol, Branford, Susan
Publicado 2022

P683: TRIALS IN PROGRESS: FIRST-IN-HUMAN STUDY OF ELVN-001, A SELECTIVE BCR::ABL1 TYROSINE KINASE INHIBITOR, IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO FAILED PREVIOUS TYROSINE...

por Lang, Fabian, Branford, Susan, P. Lyssikatos, Joseph, Collins, Helen, Hochhaus, Andreas
Publicado 2023

Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers

por Krishnan, Vaidehi, Kim, Dennis Dong Hwan, Hughes, Timothy P., Branford, Susan, Ong, S. Tiong
Publicado 2021

A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system

por Enjeti, Anoop, Granter, Neil, Ashraf, Asma, Fletcher, Linda, Branford, Susan, Rowlings, Philip, Dooley, Susan
Publicado 2015

The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro

por Eadie, Laura N., Saunders, Verity A., Branford, Susan, White, Deborah L., Hughes, Timothy P.
Publicado 2018

S151: COMBINATION OF LARGE SPLEEN AND LOW IN VIVO KINASE INHIBITION IS AN EARLY PREDICTOR OF INFERIOR MOLECULAR RESPONSE AND POOR OUTCOMES IN CHRONIC MYELOID LEUKAEMIA

por Kok, Chung, Saunders, Verity, Dang, Phuong, Shanmuganathan, Naranie, White, Deborah, Branford, Susan, Yeung, David, Hughes, Timothy
Publicado 2023

Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale

por Yoshida, Chikashi, Nakamae, Hirohisa, Fletcher, Linda, Koga, Daisuke, Sogabe, Takayuki, Matsumura, Itaru, Kanakura, Yuzuru, Branford, Susan, Naoe, Tomoki
Publicado 2016

Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib

por Kok, Chung H., Saunders, Verity A., Dang, Phuong, Shanmuganathan, Naranie, White, Deborah, Branford, Susan, Yeung, David, Hughes, Timothy P.
Publicado 2023

A comparative analysis of algorithms for somatic SNV detection in cancer

por Roberts, Nicola D., Kortschak, R. Daniel, Parker, Wendy T., Schreiber, Andreas W., Branford, Susan, Scott, Hamish S., Glonek, Garique, Adelson, David L.
Publicado 2013

Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia

por Irani, Yazad D., Kok, Chung H., Clarson, Jade, Shanmuganathan, Naranie, Branford, Susan, Yeung, David T., Ross, David M., Hughes, Timothy P., Yong, Agnes S. M.
Publicado 2023

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation

por Adnan Awad, Shady, Brück, Oscar, Shanmuganathan, Naranie, Jarvinen, Timo, Lähteenmäki, Hanna, Klievink, Jay, Ibrahim, Hazem, Kytölä, Soili, Koskenvesa, Perttu, Hughes, Timothy P., Branford, Susan, Kankainen, Matti, Mustjoki, Satu
Publicado 2022

BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia

por Pagani, Ilaria S., Dang, Phuong, Kommers, Ivar O., Goyne, Jarrad M., Nicola, Mario, Saunders, Verity A., Braley, Jodi, White, Deborah L., Yeung, David T., Branford, Susan, Hughes, Timothy P., Ross, David M.
Publicado 2018

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia

por Stein, Andrew M, Martinelli, Giovanni, Hughes, Timothy P, Müller, Martin C, Beppu, Lan, Gottardi, Enrico, Branford, Susan, Soverini, Simona, Woodman, Richard C, Hochhaus, Andreas, Kim, Dong-Wook, Saglio, Giuseppe, Radich, Jerald P
Publicado 2013

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia

por Cross, Nicholas C. P., Ernst, Thomas, Branford, Susan, Cayuela, Jean-Michel, Deininger, Michael, Fabarius, Alice, Kim, Dennis Dong Hwan, Machova Polakova, Katerina, Radich, Jerald P., Hehlmann, Rüdiger, Hochhaus, Andreas, Apperley, Jane F., Soverini, Simona
Publicado 2023